ABEO catalyst calendar

ABEONA THERAPEUTICS INC.

Upcoming catalysts
2
Cash runway
8.5 months
Cash & investments
$56M
Phase 3 programs
2

ABEONA THERAPEUTICS INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 11, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 8.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 7 concluded trials, 71% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 11, 2026 est. Next quarterly earnings (projected) Earnings —
November 15, 2031 Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds Trial Milestone Phase 4

Track ABEO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ABEO in the tracker

Recent history

DateEventTypePhase
September 15, 2026 8-K filed: Reg FD disclosure Filing —
August 13, 2026 Quarterly results filed (8-K) Earnings —
June 12, 2026 8-K filed: Leadership change Corporate —
June 10, 2026 8-K filed: Reg FD disclosure Filing —
June 4, 2026 8-K filed: Other event Filing —
May 13, 2026 Quarterly results filed (8-K) Earnings —
April 7, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
March 17, 2026 Quarterly results filed (8-K) Earnings —
March 9, 2026 8-K filed: Other event Filing —
November 12, 2025 Quarterly results filed (8-K) Earnings —
September 30, 2025 A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients Trial Milestone Phase 3
August 14, 2025 Quarterly results filed (8-K) Earnings —
July 18, 2025 8-K filed: Material agreement Corporate —
July 2, 2025 Quarterly results filed (8-K) Earnings —
May 15, 2025 Quarterly results filed (8-K) Earnings —
May 12, 2025 8-K filed: Material agreement, Other event Corporate —
April 29, 2025 8-K filed: Other event Filing —
April 29, 2025 8-K filed: Reg FD disclosure Filing —
October 18, 2022 Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) Trial Milestone Phase 3
April 7, 2022 Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB Trial Milestone Phase 1/Phase 2
March 9, 2022 Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.